{"title":"嵌合抗原受体工程过继细胞治疗AML:现状和未来展望","authors":"Yue Huang, Mi Shao, Yiyun Wang, He Huang","doi":"10.1002/imed.1031","DOIUrl":null,"url":null,"abstract":"<p>Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B-cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor-based cell therapy in AML preclinical studies and clinical trials with potential AML-associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor-based cell therapy options for patients with AML.</p>","PeriodicalId":73348,"journal":{"name":"Immunomedicine","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imed.1031","citationCount":"0","resultStr":"{\"title\":\"Chimeric antigen receptor-engineered adoptive cell therapy for AML: Current status and future perspectives\",\"authors\":\"Yue Huang, Mi Shao, Yiyun Wang, He Huang\",\"doi\":\"10.1002/imed.1031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B-cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor-based cell therapy in AML preclinical studies and clinical trials with potential AML-associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor-based cell therapy options for patients with AML.</p>\",\"PeriodicalId\":73348,\"journal\":{\"name\":\"Immunomedicine\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imed.1031\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/imed.1031\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunomedicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imed.1031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chimeric antigen receptor-engineered adoptive cell therapy for AML: Current status and future perspectives
Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B-cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor-based cell therapy in AML preclinical studies and clinical trials with potential AML-associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor-based cell therapy options for patients with AML.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
